rs880071

Variant summary

Our verdict is Benign. Variant got -21 ACMG points: 0P and 21B. BP4_StrongBP6_Very_StrongBP7BA1

The NM_002474.3(MYH11):​c.2061C>T​(p.Ser687Ser) variant causes a splice region, synonymous change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0674 in 1,613,574 control chromosomes in the GnomAD database, including 4,133 homozygotes. In-silico tool predicts a benign outcome for this variant. 1/1 splice prediction tools predict no significant impact on normal splicing. Variant has been reported in ClinVar as Benign (★★).

Frequency

Genomes: 𝑓 0.063 ( 335 hom., cov: 32)
Exomes 𝑓: 0.068 ( 3798 hom. )

Consequence

MYH11
NM_002474.3 splice_region, synonymous

Scores

2

Clinical Significance

Benign criteria provided, multiple submitters, no conflicts B:14

Conservation

PhyloP100: -3.89
Variant links:
Genes affected
MYH11 (HGNC:7569): (myosin heavy chain 11) The protein encoded by this gene is a smooth muscle myosin belonging to the myosin heavy chain family. The gene product is a subunit of a hexameric protein that consists of two heavy chain subunits and two pairs of non-identical light chain subunits. It functions as a major contractile protein, converting chemical energy into mechanical energy through the hydrolysis of ATP. A chromosomal rearrangement involving this gene is associated with acute myeloid leukemia of the M4Eo subtype. Mutations in this gene are associated with visceral myopathy, megacystis-microcolon-intestinal hypoperistalsis syndrome 2, and familial thoracic aortic aneurysm 4. [provided by RefSeq, May 2022]

Genome browser will be placed here

ACMG classification

Classification made for transcript

Verdict is Benign. Variant got -21 ACMG points.

BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.95).
BP6
Variant 16-15748166-G-A is Benign according to our data. Variant chr16-15748166-G-A is described in ClinVar as [Benign]. Clinvar id is 138328.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr16-15748166-G-A is described in Lovd as [Benign].
BP7
Synonymous conserved (PhyloP=-3.89 with no splicing effect.
BA1
GnomAd4 highest subpopulation (EAS) allele frequency at 95% confidence interval = 0.164 is higher than 0.05.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
MYH11NM_002474.3 linkc.2061C>T p.Ser687Ser splice_region_variant, synonymous_variant Exon 17 of 41 ENST00000300036.6 NP_002465.1 P35749-1A0A024QZJ4
MYH11NM_001040113.2 linkc.2082C>T p.Ser694Ser splice_region_variant, synonymous_variant Exon 18 of 43 ENST00000452625.7 NP_001035202.1 P35749-3
MYH11NM_001040114.2 linkc.2082C>T p.Ser694Ser splice_region_variant, synonymous_variant Exon 18 of 42 NP_001035203.1 P35749-2
MYH11NM_022844.3 linkc.2061C>T p.Ser687Ser splice_region_variant, synonymous_variant Exon 17 of 42 NP_074035.1 P35749-4A0A024QZJ6

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
MYH11ENST00000300036.6 linkc.2061C>T p.Ser687Ser splice_region_variant, synonymous_variant Exon 17 of 41 1 NM_002474.3 ENSP00000300036.5 P35749-1
MYH11ENST00000452625.7 linkc.2082C>T p.Ser694Ser splice_region_variant, synonymous_variant Exon 18 of 43 1 NM_001040113.2 ENSP00000407821.2 P35749-3

Frequencies

GnomAD3 genomes
AF:
0.0630
AC:
9583
AN:
152160
Hom.:
337
Cov.:
32
show subpopulations
Gnomad AFR
AF:
0.0542
Gnomad AMI
AF:
0.0341
Gnomad AMR
AF:
0.0461
Gnomad ASJ
AF:
0.0853
Gnomad EAS
AF:
0.173
Gnomad SAS
AF:
0.0706
Gnomad FIN
AF:
0.0281
Gnomad MID
AF:
0.0728
Gnomad NFE
AF:
0.0677
Gnomad OTH
AF:
0.0692
GnomAD3 exomes
AF:
0.0649
AC:
16247
AN:
250184
Hom.:
741
AF XY:
0.0660
AC XY:
8941
AN XY:
135424
show subpopulations
Gnomad AFR exome
AF:
0.0512
Gnomad AMR exome
AF:
0.0277
Gnomad ASJ exome
AF:
0.0902
Gnomad EAS exome
AF:
0.185
Gnomad SAS exome
AF:
0.0641
Gnomad FIN exome
AF:
0.0296
Gnomad NFE exome
AF:
0.0634
Gnomad OTH exome
AF:
0.0644
GnomAD4 exome
AF:
0.0678
AC:
99136
AN:
1461296
Hom.:
3798
Cov.:
34
AF XY:
0.0680
AC XY:
49460
AN XY:
726944
show subpopulations
Gnomad4 AFR exome
AF:
0.0528
Gnomad4 AMR exome
AF:
0.0304
Gnomad4 ASJ exome
AF:
0.0894
Gnomad4 EAS exome
AF:
0.152
Gnomad4 SAS exome
AF:
0.0646
Gnomad4 FIN exome
AF:
0.0307
Gnomad4 NFE exome
AF:
0.0677
Gnomad4 OTH exome
AF:
0.0783
GnomAD4 genome
AF:
0.0630
AC:
9586
AN:
152278
Hom.:
335
Cov.:
32
AF XY:
0.0606
AC XY:
4513
AN XY:
74462
show subpopulations
Gnomad4 AFR
AF:
0.0542
Gnomad4 AMR
AF:
0.0460
Gnomad4 ASJ
AF:
0.0853
Gnomad4 EAS
AF:
0.173
Gnomad4 SAS
AF:
0.0702
Gnomad4 FIN
AF:
0.0281
Gnomad4 NFE
AF:
0.0676
Gnomad4 OTH
AF:
0.0681
Alfa
AF:
0.0686
Hom.:
179
Bravo
AF:
0.0638
Asia WGS
AF:
0.117
AC:
407
AN:
3478
EpiCase
AF:
0.0677
EpiControl
AF:
0.0616

ClinVar

Significance: Benign
Submissions summary: Benign:14
Revision: criteria provided, multiple submitters, no conflicts
LINK: link

Submissions by phenotype

not specified Benign:3
Nov 16, 2012
GeneDx
Significance: Benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing

This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease. -

-
PreventionGenetics, part of Exact Sciences
Significance: Benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

Apr 04, 2013
Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine
Significance: Benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing

Ser694Ser in exon 18 of MYH11: This variant is not expected to have clinical sig nificance because it does not alter an amino acid residue and is not located wit hin the splice consensus sequence. It has been identified in 6.7% (576/8600) of European American chromosomes from a broad population by the NHLBI Exome Sequenc ing Project (http://evs.gs.washington.edu/EVS; dbSNP rs880071). -

Familial thoracic aortic aneurysm and aortic dissection Benign:3
Feb 26, 2015
Ambry Genetics
Significance: Benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing

General population or subpopulation frequency is too high to be a pathogenic mutation based on disease/syndrome prevalence and penetrance;Seen in trans with a mutation or in homozygous state in individual without severe disease for that gene -

Mar 07, 2018
Color Diagnostics, LLC DBA Color Health
Significance: Benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

Feb 05, 2024
All of Us Research Program, National Institutes of Health
Significance: Benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

Aortic aneurysm, familial thoracic 4 Benign:3
Jan 13, 2018
Illumina Laboratory Services, Illumina
Significance: Benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing

This variant was observed in the ICSL laboratory as part of a predisposition screen in an ostensibly healthy population. It had not been previously curated by ICSL or reported in the Human Gene Mutation Database (HGMD: prior to June 1st, 2018), and was therefore a candidate for classification through an automated scoring system. Utilizing variant allele frequency, disease prevalence and penetrance estimates, and inheritance mode, an automated score was calculated to assess if this variant is too frequent to cause the disease. Based on the score and internal cut-off values, a variant classified as benign is not then subjected to further curation. The score for this variant resulted in a classification of benign for this disease. -

Sep 05, 2021
Genome-Nilou Lab
Significance: Benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

Feb 04, 2025
Labcorp Genetics (formerly Invitae), Labcorp
Significance: Benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

not provided Benign:2
-
Breakthrough Genomics, Breakthrough Genomics
Significance: Benign
Review Status: criteria provided, single submitter
Collection Method: not provided

- -

Nov 27, 2024
ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories
Significance: Benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

Visceral myopathy 2 Benign:1
Sep 05, 2021
Genome-Nilou Lab
Significance: Benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

Megacystis-microcolon-intestinal hypoperistalsis syndrome 2 Benign:1
Sep 05, 2021
Genome-Nilou Lab
Significance: Benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

Cardiovascular phenotype Benign:1
Nov 24, 2014
Ambry Genetics
Significance: Benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing

This alteration is classified as benign based on a combination of the following: population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
-0.95
CADD
Benign
0.0040
DANN
Benign
0.46

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

LitVar

Below is the list of publications found by LitVar. It may be empty.

Other links and lift over

dbSNP: rs880071; hg19: chr16-15842023; COSMIC: COSV55545525; COSMIC: COSV55545525; API